类风湿关节炎中两种bDMARD联合治疗的安全性:系统综述与荟萃分析
该系统综述与荟萃分析评估了类风湿关节炎患者联合使用两种生物制剂改善病情抗风湿药(bDMARDs)的安全性。纳入6项对照研究共623例患者,结果显示联合治疗组严重不良事件(SAEs)和总不良事件发生率显著高于单药治疗组,全剂量联合时严重感染风险也显著增加。结论提示联合两种bDMARDs在治疗前12个月内可能增加SAEs风险。
要点
- 联合两种bDMARDs的RA患者SAEs发生率显著高于单药治疗(14.9% vs 6.0%,OR 2.51)。
- 全剂量联合两种bDMARDs时严重感染风险显著增加(6.7% vs 0.6%,OR 5.58)。
- 联合治疗组总不良事件发生率也显著升高(94.6% vs 89.1%,OR 2.07)。
核心结论
- 类风湿关节炎患者联合使用两种bDMARDs在治疗前12个月内可能增加严重不良事件风险。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、EMBASE、Cochrane Library、Scopus、ClinicalTrials.gov及WHO ICTRP,纳入6项对照研究共623例患者(联合治疗410例,单药治疗213例),中位随访9.5个月(范围6-12个月)。
主要发现
- 联合治疗组SAEs发生率为14.9%,单药治疗组为6.0%,OR 2.51(95%CI 1.29-4.89),I2 0%。
- 联合治疗组总不良事件发生率为94.6%,单药治疗组为89.1%,OR 2.07(95%CI 1.11-3.86),I2 0%。
- 全剂量联合两种bDMARDs亚组中,严重感染发生率为6.7% vs 0.6%,OR 5.58(95%CI 1.25-24.90),I2 0%。
- 全剂量联合亚组中SAEs风险仍显著升高(17.1% vs 6.2%,OR 2.72,95%CI 1.30-5.69),I2 0%。
关键数值与推荐
- 主要结局为严重不良事件(SAEs)发生率,采用随机效应模型计算OR及95%CI。
- 联合治疗组SAEs OR 2.51(95%CI 1.29-4.89),总不良事件OR 2.07(95%CI 1.11-3.86)。
- 全剂量联合亚组严重感染OR 5.58(95%CI 1.25-24.90),SAEs OR 2.72(95%CI 1.30-5.69)。
临床怎么用
- 临床应避免在类风湿关节炎患者中联合使用两种bDMARDs,因可能增加严重不良事件及严重感染风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We performed a systematic review and meta-analysis of the current literature to assess the safety of combining two biologic disease-modifying antirheumatic drugs (bDMARDs) in the treatment of rheumatoid arthritis (RA). METHODS: We systematically searched for controlled studies evaluating safety in patients with RA treated with two bDMARDs independently of dose-regimen. Databases used were MEDLINE (via Pubmed), EMBase, Cochrane Library, Scopus, ClinicalTrials.gov, and the WHO International Clinical Trials Registry platform. A meta-analysis was performed between groups on combination therapy and patients on single therapy using random effects model calculating odds ratio (OR) as well as 95% confidence interval (CI). The primary outcome was the rate of serious adverse events (SAEs). RESULTS: Six studies with a total of 623 patients (410 on combination therapy and 213 on single therapy) were included. Median follow-up was 9.5 months (range 6-12 months). There was a significant increase in SAEs in the combination group (14.9 vs 6.0%, OR 2.51, 95% CI 1.29-4.89, I2 0%) as well as in total adverse events (94.6 vs 89.1%, OR 2.07, 95% CI 1.11-3.86, I2 0%). When performing subgroup analysis in patients receiving only full-dose of both bDMARDs there was a significant increase in serious infections (6.7 vs 0.6%, OR 5.58, 95% CI 1.25-24.90, I2 0%) and the risk of SAEs remained significantly higher (17.1 vs 6.2%, OR 2.72, 95% CI 1.30-5.69, I2 0%). CONCLUSION: Our findings suggest that combination therapy with two bDMARDs in RA appears to increase the risk of SAEs during the first twelve months of treatment.
引用
- Boleto G, Kanagaratnam L, Dramé M, et al. Safety of combination therapy with two bDMARDs in patients with rheumatoid arthritis: A systematic review and meta-analysis. Semin Arthritis Rheum. 2018. PMID: 30638975. doi:10.1016/j.semarthrit.2018.12.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。